Title : Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Pub. Date : 2016 Mar

PMID : 26795874






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the ReSPonD trial we aimed to assess whether ameliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability. Rivastigmine acetylcholinesterase (Cartwright blood group) Homo sapiens